Clinical trial · Observational
Serial Epstein-Barr Virus DNA Surveillance in Nasopharyngeal Carcinoma Patients
Serial Epstein-Barr Virus DNA Surveillance During Treatment in Non-metastatic Nasopharyngeal Carcinoma Patients
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Endemic nasopharyngeal carcinoma (NPC) is invariably associated with Epstein-barr virus (EBV) infection. Plasma EBV DAN detected by polymerase chain reaction (PCR)-based assays can provide important informations of disease screening, disease relapse, and risks classification. In this study, the investigators will explore the impact of serial plasma EBV DNA during chemotherapy and radiotherapy on initial tumor response and long-term survival in patients with non-metastatic nasopharyngeal carcinoma
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Nasopharyngeal Carcinoma | Nasopharyngeal Carcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Plasma EBV DNA | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- observational cohort
- description
- Patients enrolled in this observational cohort would have regular blood taking for EBV DNA examination at baseline, after every cycle of chemotherapy, every week during radiotherapy, and 1-3 months after chemo-radiotherapy until EBV DNA becomes undetectable for at least two times.
- interventionNames
- Diagnostic Test: Plasma EBV DNA
Primary outcomes (1)
- measure
- Progression-free survival
- timeFrame
- 3 years
- description
- Progression-free survival is calculated from the date of diagnosis of NPC to the date of progression of NPC or the date of death from any cause, whichever comes earlier.
Secondary outcomes (4)
- measure
- overall survival
- timeFrame
- 3 years
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Patients with newly histologically confirmed non-keratinizing carcinoma (according to WHO histological type) 2. No evidence of distant metastasis (M0) 3. Receive standard radical treatment 4. Not exhibiting overt psychopathology, and willing to participate and written informed consent was obtained Exclusion Criteria: 1. WHO type keratinizing squamous cell carcinoma or basaloid squamous cell carcinoma. 2. Treatment with palliative intent 3. Previous chemotherapy or radiotherapy (except non-melanomatous skin cancers outside the intended RT treatment volume) 4. Severe intercurrent disease
References
Publications (1)
- DERIVEDLv J, Zheng DX, Liang JH, Zhang N, Ye ZL, Xu XD, Chua MLK, Zhang LL, Du ZM, Zhang ZC, Li WF, Tang LL, Chen L, Mao YP, Guo R, Chen YP, Lin L, Zhang Y, Liu X, Xu C, Li ZX, Xu LX, Yang PY, Chen K, Bin D, Gao TS, Yan JY, Chen LS, Huang SH, Zhao HY, Hong SB, Jie YS, Huang HL, Tang XH, Yun JP, Liu LZ, Tian L, Li HJ, Li JB, Zhou GQ, Ma J, Sun Y. Risk-adaptive therapy guided by dynamic ctDNA in nasopharyngeal carcinoma. Nature. 2026 Apr;652(8110):731-739. doi: 10.1038/s41586-026-10244-w. Epub 2026 Mar 11. PMID 41813900